デフォルト表紙
市場調査レポート
商品コード
1798332

アピキサバンの世界市場

Apixaban

出版日
ページ情報
英文 282 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=153.26円
アピキサバンの世界市場
出版日: 2025年08月26日
発行: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
ページ情報: 英文 282 Pages
納期: 即日から翌営業日
GIIご利用のメリット

  • 全表示

  • 概要
  • 目次
概要

アピキサバンの世界市場は2030年までに272億米ドルに達する見込み

2024年に181億米ドルと推定されるアピキサバンの世界市場は、分析期間2024-2030年にCAGR 7.0%で成長し、2030年には272億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるカプセル剤は、CAGR 8.1%を記録し、分析期間終了時には194億米ドルに達すると予測されます。錠剤セグメントの成長率は、分析期間中CAGR 4.5%と推定されます。

米国市場は49億米ドルと推定、中国はCAGR 11.1％で成長予測

米国のアピキサバン市場は、2024年に49億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに57億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは11.1%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.4%と6.8%と予測されています。欧州では、ドイツがCAGR 4.6%で成長すると予測されています。

世界のアピキサバン市場- 主要動向と促進要因のまとめ

アピキサバンが現代の心血管系治療における主要な抗凝固剤となった理由とは？

アピキサバンは、血栓塞栓症の予防と治療のために最も広く使用され、臨床的に信頼されている抗凝固薬の1つとして登場しました。直接経口抗凝固薬（DOAC）として、アピキサバンは凝固カスケードの重要な酵素である第Xa因子を選択的に阻害し、血栓の形成を抑制します。アピキサバンの人気は、ワルファリンのような従来の抗凝固薬と比較して、優れた安全性プロファイル、一貫した薬物動態、利便性によるところが大きいです。ワルファリンと異なり、アピキサバンは日常的な血液モニタリングや食事制限を必要としないため、患者の服薬アドヒアランスとQOLが大幅に向上します。非弁膜症性心房細動患者における脳卒中予防、深部静脈血栓症（DVT）、肺塞栓症（PE）の治療、およびこれらのイベントの再発リスクの低減など、さまざまな適応症で承認されています。心血管疾患や加齢に伴う血栓性疾患の世界の負担は、特に高齢化した集団において、有効で安全な抗凝固療法に対する需要を高めています。ARISTOTLEやAMPLIFYなどの臨床試験により、アピキサバンは旧来の抗凝固薬と比較して有効性が高く、大出血を起こしにくいことが示されており、第一選択薬としての位置づけが強まっています。アピキサバンは、1日2回の経口投与と頭蓋内出血のリスクの低減により、長期的な抗凝固療法のニーズに対して非常に管理しやすいソリューションを提供します。アピキサバンの入院および外来での採用が増加していることは、心血管系治療におけるエビデンスに基づく、患者に優しい治療モデルへの幅広いシフトを反映しています。

調査と臨床ガイドラインの進歩は、アピキサバンの使用をどのように形成していますか？

心血管研究における最近の進歩や臨床ガイドラインの進化は、アピキサバンの処方や投与方法を多様な患者集団に大きく変化させています。実臨床におけるアピキサバンの有効性に関する継続的な調査により、当初の規制適応を超えた使用を裏付ける豊富なデータが得られています。例えば、がん関連血栓症、肥満、腎機能障害、整形外科手術後の回復期の患者におけるアピキサバンのパフォーマンスが研究され、複雑で高リスクの患者群に広く受け入れられるに至っています。米国心臓病学会や欧州心臓病学会を含む主要な心臓血管学会のガイドラインでは、有効性と安全性のバランスに優れていることから、多くの臨床場面でワルファリンよりもアピキサバンを推奨する傾向が強まっています。さらに、アピキサバンは併用療法レジメンや、リバーロキサバンやエドキサバンなどの他のDOACとの比較においても検討されており、臨床的な意思決定において、より微妙でテーラーメイドなアプローチに貢献しています。薬物代謝に影響を及ぼす可能性のある遺伝的変異を解析することで、より個別化された抗凝固療法が可能になる可能性があります。さらに、腎機能が低下している患者や出血リスクの高い高齢者に対する投与量の調整など、特定のニーズに対応するための投与戦略も洗練されつつあります。病院やヘルスケアシステムは、アピキサバンを電子カルテ、遠隔医療プラットフォーム、リスク評価ツールに統合した包括的な抗凝固療法管理プログラムを開発しており、これらすべてが治療の最適化と転帰の改善を目的としています。血栓症に対する科学的理解が進むにつれ、アピキサバンは、強力なエビデンスベースと臨床場面における適応性から、抗血栓療法の礎石として位置付けられ続けています。

市場力学、患者人口統計、競合情勢はアピキサバンの世界的普及にどのような影響を与えるか？

アピキサバンの市場成長と普及は、患者人口動態の変化、地域のヘルスケアインフラ、価格ダイナミクス、抗凝固剤セグメント内の競争状況によって大きく左右されます。人口の高齢化と心房細動、静脈血栓塞栓症、術後の血栓合併症の発生率の上昇に伴い、利用しやすく効果的な抗凝固薬の選択肢に対する需要が世界的に急増しています。アピキサバンは、特に医療制度の整った新興経済諸国において、負担の大きい旧来の代替療法よりも新しい経口療法を優先し、大きな市場シェアを獲得しています。規制当局の承認や保険適用が確立している米国や欧州では、アピキサバンは処方者からの信頼も厚く、患者にも親しまれています。しかし、新興市場においては、コストやジェネリック医薬品の有無が医薬品へのアクセスを左右することが多いです。特許保護期間が満了し、バイオシミラー医薬品の競合が増加するにつれて、特にヘルスケア予算に制約のある地域では価格圧力が強まることが予想されます。製薬会社は、教育プログラム、保健省との提携、国のフォーミュラへの組み入れなどを通じて、市場への浸透を拡大するために積極的に取り組んでいます。同時に、競合情勢は進化しており、新しいDOACがこの分野に参入し、直接比較による処方者の嗜好が形成され続けています。投与の利便性、最小限の薬物相互作用、モニタリング要件の軽減といった患者中心の要因が、特に外来患者やプライマリ・ケアにおける競合優位性をもたらしています。テレヘルスの採用とデジタル処方ツールは、患者のアクセスとアドヒアランスをさらに向上させています。このような多面的な市場の力は、アピキサバンの現在の成功を支えているだけでなく、世界中のより広範で多様な治療集団への継続的な拡大に道を開いています。

アピキサバン世界市場の継続的成長の原動力は？

アピキサバン市場の成長は、疫学的動向、臨床的利点、経済的考慮、進化するヘルスケア提供モデルなど、相互に関連するいくつかの要因によって牽引されています。心房細動、静脈血栓塞栓症、術後の血栓リスクなどの世界の有病率の増加は、特に高齢化社会がこれらの事象に罹患しやすくなるにつれて、主要な促進要因の一つとなっています。アピキサバンは、重篤な出血のリスクを抑えながら効果的な抗凝固療法を行うことができ、また、使い勝手がよく、定期的な血液検査が不要であることから、患者にも医師にも好まれています。これと並行して、多くの国際的なガイドラインによる臨床的な推奨が、本薬の信頼性と標準治療の地位を高め続けています。ジェネリック医薬品の入手可能性が高まり、価格戦略も改善されたことで、これまでは経済的な理由でアクセスが制限されていた低所得層やコストに敏感な市場にも、この薬が浸透しつつあります。病院での再入院を減らし、慢性疾患をより効率的に管理しようとするヘルスケアシステムは、統合ケア・パスにアピキサバンを組み込んでおり、遠隔モニタリングやコンプライアンス追跡を容易にするデジタル・ツールに支えられています。製薬会社も継続的な調査に投資し、新たな適応症や患者層を開拓して、治療上の有用性をさらに広げています。脳卒中予防と血栓症啓発を目的とした公衆衛生キャンペーンは、早期介入と長期抗凝固療法への需要を高めており、これはアピキサバンのプロファイルによく合致しています。これらの要因が相まって、アピキサバンは持続的かつ堅調な世界的成長に寄与しており、現在の抗凝固療法のニーズに対する選択薬としてだけでなく、進化する将来の心血管・血栓塞栓症管理における戦略的支柱として位置づけられています。

セグメント

剤形（カプセル剤、錠剤）、エンドユーザー（病院エンドユーザー、クリニックエンドユーザー、その他エンドユーザー）

調査対象企業の例

  • Aurobindo Pharma Limited
  • Aspen Pharmacare Holdings Limited
  • AstraZeneca
  • Bayer
  • Bristol-Myers Squibb
  • Cipla Limited
  • Daiichi Sankyo Company Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eisai Co. Ltd
  • F. Hoffmann-La Roche Ltd
  • Glenmark Pharmaceuticals Ltd.
  • Hetero Drugs Ltd
  • Johnson & Johnson
  • Lupin Limited
  • Merck & Co. Inc.（MSD）
  • Pfizer Inc.
  • Sanofi S.A.
  • Sandoz Group AG（Novartis）
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Viatris Inc.（formerly Mylan）

AI統合

Global Industry Analystsは、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP38487

Global Apixaban Market to Reach US$27.2 Billion by 2030

The global market for Apixaban estimated at US$18.1 Billion in the year 2024, is expected to reach US$27.2 Billion by 2030, growing at a CAGR of 7.0% over the analysis period 2024-2030. Capsule Form, one of the segments analyzed in the report, is expected to record a 8.1% CAGR and reach US$19.4 Billion by the end of the analysis period. Growth in the Tablet Form segment is estimated at 4.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.9 Billion While China is Forecast to Grow at 11.1% CAGR

The Apixaban market in the U.S. is estimated at US$4.9 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$5.7 Billion by the year 2030 trailing a CAGR of 11.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.4% and 6.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.6% CAGR.

Global Apixaban Market - Key Trends & Drivers Summarized

Why Has Apixaban Become a Leading Anticoagulant in Modern Cardiovascular Care?

Apixaban has emerged as one of the most widely used and clinically trusted anticoagulant medications for preventing and treating thromboembolic disorders. As a direct oral anticoagulant (DOAC), apixaban selectively inhibits Factor Xa, a crucial enzyme in the coagulation cascade, thereby reducing the formation of blood clots. Its rise in popularity is largely due to its superior safety profile, consistent pharmacokinetics, and convenience compared to traditional anticoagulants like warfarin. Unlike warfarin, apixaban does not require routine blood monitoring or dietary restrictions, which significantly improves patient adherence and quality of life. It is approved for a range of indications including stroke prevention in patients with non-valvular atrial fibrillation, treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), and for reducing the risk of recurrence of these events. The global burden of cardiovascular diseases and age-related thrombotic conditions has increased demand for effective and safe anticoagulant therapy, particularly in aging populations. Clinical trials, such as ARISTOTLE and AMPLIFY, have shown apixaban to be both more effective and less likely to cause major bleeding than some older anticoagulants, reinforcing its position as a front-line therapy. With its twice-daily oral dosing and reduced risk of intracranial hemorrhage, apixaban offers a highly manageable solution for long-term anticoagulation needs. Its growing adoption in both inpatient and outpatient settings reflects a broader shift toward evidence-based, patient-friendly treatment models for cardiovascular care.

How Are Advancements in Research and Clinical Guidelines Shaping the Use of Apixaban?

Recent advancements in cardiovascular research and evolving clinical guidelines are significantly shaping how apixaban is prescribed and administered across diverse patient populations. Continued investigation into its efficacy in real-world settings has provided a wealth of data supporting its use beyond initial regulatory indications. For instance, studies have examined apixaban’s performance in patients with cancer-associated thrombosis, obesity, renal impairment, and post-orthopedic surgery recovery, leading to its broader acceptance in complex and high-risk patient groups. Guidelines from major cardiovascular societies, including the American College of Cardiology and European Society of Cardiology, have increasingly recommended apixaban over warfarin in many clinical scenarios due to its superior balance of efficacy and safety. Furthermore, apixaban has been explored in combination therapy regimens and in comparison with other DOACs like rivaroxaban and edoxaban, contributing to more nuanced and tailored approaches in clinical decision-making. Pharmacogenomics is also playing a role, as researchers analyze genetic variations that might influence drug metabolism, offering future possibilities for even more personalized anticoagulant therapy. Additionally, dosing strategies are being refined to address specific needs, such as dose adjustments for patients with impaired kidney function or elderly individuals at higher risk of bleeding. Hospitals and healthcare systems are developing comprehensive anticoagulation management programs that integrate apixaban into electronic health records, telemedicine platforms, and risk assessment tools, all designed to optimize therapy and improve outcomes. As the scientific understanding of thrombosis evolves, apixaban continues to be positioned as a cornerstone in antithrombotic care, benefiting from a strong evidence base and adaptability across clinical contexts.

How Do Market Dynamics, Patient Demographics, and Competitive Landscape Impact Apixaban’s Global Uptake?

The market growth and adoption of apixaban are deeply influenced by shifting patient demographics, regional healthcare infrastructure, pricing dynamics, and competitive activity within the anticoagulant segment. As populations age and the incidence of atrial fibrillation, venous thromboembolism, and post-surgical clot complications rise, the demand for accessible, effective anticoagulant options has surged globally. Apixaban has managed to gain substantial market share, especially in developed economies with robust healthcare systems that prioritize newer oral therapies over older, more burdensome alternatives. In the United States and Europe, where regulatory approvals and insurance coverage are well established, apixaban enjoys wide prescriber confidence and patient familiarity. However, in emerging markets, access is often influenced by cost considerations and the availability of generic formulations. As patent protections expire and biosimilar competition increases, pricing pressures are expected to intensify, particularly in regions with constrained healthcare budgets. Pharmaceutical companies are actively working to expand market penetration through education programs, partnerships with health ministries, and inclusion in national formularies. At the same time, the competitive landscape is evolving, with newer DOACs entering the field and head-to-head comparisons continuing to shape prescriber preferences. Patient-centric factors such as dosing convenience, minimal drug interactions, and reduced monitoring requirements give apixaban a competitive edge, especially in outpatient and primary care settings. Telehealth adoption and digital prescription tools are further enhancing patient access and adherence. These multifaceted market forces are not only sustaining apixaban’s current success but also paving the way for its continued expansion into broader and more diverse treatment populations worldwide.

What Is Driving the Continued Growth of the Global Apixaban Market?

The growth in the apixaban market is driven by several interconnected factors that span epidemiological trends, clinical advantages, economic considerations, and evolving healthcare delivery models. The increasing global prevalence of conditions like atrial fibrillation, venous thromboembolism, and post-surgical clot risks is one of the foremost drivers, especially as aging populations become more susceptible to these events. Apixaban’s ability to offer effective anticoagulation with a lower risk of serious bleeding, combined with its user-friendly administration and absence of routine blood testing, makes it a preferred choice among both patients and physicians. In parallel, clinical endorsement from numerous international guidelines continues to bolster its credibility and standard of care status. The growing availability of generic versions and improved pricing strategies are helping to expand its reach into lower-income and cost-sensitive markets, where affordability had previously limited access. Healthcare systems seeking to reduce hospital readmissions and manage chronic conditions more efficiently are incorporating apixaban into integrated care pathways, supported by digital tools that facilitate remote monitoring and compliance tracking. Pharmaceutical companies are also investing in continued research, exploring new indications and patient segments to further widen its therapeutic utility. Public health campaigns aimed at stroke prevention and thrombosis awareness have increased demand for early intervention and long-term anticoagulation, which aligns well with apixaban’s profile. Together, these drivers are contributing to sustained and robust global growth, positioning apixaban not just as a drug of choice for present-day anticoagulation needs but as a strategic pillar in the evolving future of cardiovascular and thromboembolic disease management.

SCOPE OF STUDY:

The report analyzes the Apixaban market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Form (Capsule Form, Tablet Form); End-User (Hospitals End-User, Clinics End-User, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

  • Aurobindo Pharma Limited
  • Aspen Pharmacare Holdings Limited
  • AstraZeneca
  • Bayer
  • Bristol-Myers Squibb
  • Cipla Limited
  • Daiichi Sankyo Company Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eisai Co. Ltd
  • F. Hoffmann-La Roche Ltd
  • Glenmark Pharmaceuticals Ltd.
  • Hetero Drugs Ltd
  • Johnson & Johnson
  • Lupin Limited
  • Merck & Co. Inc. (MSD)
  • Pfizer Inc.
  • Sanofi S.A.
  • Sandoz Group AG (Novartis)
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Viatris Inc. (formerly Mylan)

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Apixaban - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence of Atrial Fibrillation and Venous Thromboembolism Spurs Demand for Apixaban Therapy
    • Here's How Clinical Preference for NOACs Over Warfarin Strengthens the Business Case for Apixaban Use
    • Growing Geriatric Population with Comorbidities Throws the Spotlight on Safer Anticoagulation Profiles Like Apixaban
    • Favorable Risk-Benefit Ratio in Stroke Prevention Drives Widespread Adoption in Cardiology and Primary Care
    • Here's the Story: Superior Safety Profile in Bleeding Risk Compared to Other Anticoagulants Sustains Market Leadership
    • Post-Surgical Thromboprophylaxis Guidelines Expand the Addressable Market for Apixaban in Orthopedic Patients
    • Expanding Use in Cancer-Associated Thrombosis Opens Niche Therapeutic Opportunities for Apixaban
    • Here's How Strong Real-World Evidence and Head-to-Head Trial Outcomes Support Prescriber Confidence in Apixaban
    • Growth of Oral Anticoagulant Markets in Asia-Pacific and Latin America Accelerates Geographic Expansion of Apixaban Access
    • Patent Expiry and Generic Entry Create Pricing Pressure But Also Drive Volume Growth in Cost-Sensitive Markets
    • Increased Investment in Stroke Awareness and AFib Screening Programs Supports Early Diagnosis and Long-Term Apixaban Use
    • Here's How Digital Therapeutics and Remote Monitoring Tools Strengthen Adherence and Dosing Compliance in Anticoagulant Therapy
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Apixaban Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Apixaban by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Apixaban by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Apixaban by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Capsule Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Capsule Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Capsule Form by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Tablet Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Tablet Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Tablet Form by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Hospitals End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Clinics End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Clinics End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Clinics End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Apixaban Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Apixaban by Form - Capsule Form and Tablet Form - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Apixaban by Form - Capsule Form and Tablet Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Apixaban by Form - Percentage Breakdown of Value Sales for Capsule Form and Tablet Form for the Years 2014, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Apixaban by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Apixaban by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Apixaban by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Apixaban by Form - Capsule Form and Tablet Form - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Apixaban by Form - Capsule Form and Tablet Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Apixaban by Form - Percentage Breakdown of Value Sales for Capsule Form and Tablet Form for the Years 2014, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Apixaban by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Apixaban by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Apixaban by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • JAPAN
    • Apixaban Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Apixaban by Form - Capsule Form and Tablet Form - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Apixaban by Form - Capsule Form and Tablet Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Apixaban by Form - Percentage Breakdown of Value Sales for Capsule Form and Tablet Form for the Years 2014, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Apixaban by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Apixaban by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Apixaban by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • CHINA
    • Apixaban Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Apixaban by Form - Capsule Form and Tablet Form - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Apixaban by Form - Capsule Form and Tablet Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: China 16-Year Perspective for Apixaban by Form - Percentage Breakdown of Value Sales for Capsule Form and Tablet Form for the Years 2014, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Apixaban by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Apixaban by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: China 16-Year Perspective for Apixaban by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • EUROPE
    • Apixaban Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Apixaban by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Apixaban by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Apixaban by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Apixaban by Form - Capsule Form and Tablet Form - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Apixaban by Form - Capsule Form and Tablet Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Apixaban by Form - Percentage Breakdown of Value Sales for Capsule Form and Tablet Form for the Years 2014, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Apixaban by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Apixaban by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Apixaban by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • FRANCE
    • Apixaban Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Apixaban by Form - Capsule Form and Tablet Form - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Apixaban by Form - Capsule Form and Tablet Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: France 16-Year Perspective for Apixaban by Form - Percentage Breakdown of Value Sales for Capsule Form and Tablet Form for the Years 2014, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Apixaban by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Apixaban by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: France 16-Year Perspective for Apixaban by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • GERMANY
    • Apixaban Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Apixaban by Form - Capsule Form and Tablet Form - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Apixaban by Form - Capsule Form and Tablet Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Apixaban by Form - Percentage Breakdown of Value Sales for Capsule Form and Tablet Form for the Years 2014, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Apixaban by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Apixaban by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Apixaban by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Apixaban by Form - Capsule Form and Tablet Form - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Apixaban by Form - Capsule Form and Tablet Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Apixaban by Form - Percentage Breakdown of Value Sales for Capsule Form and Tablet Form for the Years 2014, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Apixaban by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Apixaban by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Apixaban by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Apixaban Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Apixaban by Form - Capsule Form and Tablet Form - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Apixaban by Form - Capsule Form and Tablet Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Apixaban by Form - Percentage Breakdown of Value Sales for Capsule Form and Tablet Form for the Years 2014, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Apixaban by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Apixaban by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Apixaban by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Apixaban by Form - Capsule Form and Tablet Form - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Apixaban by Form - Capsule Form and Tablet Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for Apixaban by Form - Percentage Breakdown of Value Sales for Capsule Form and Tablet Form for the Years 2014, 2025 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Apixaban by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Apixaban by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Apixaban by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Apixaban by Form - Capsule Form and Tablet Form - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Apixaban by Form - Capsule Form and Tablet Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for Apixaban by Form - Percentage Breakdown of Value Sales for Capsule Form and Tablet Form for the Years 2014, 2025 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Apixaban by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Apixaban by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Apixaban by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Apixaban by Form - Capsule Form and Tablet Form - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Apixaban by Form - Capsule Form and Tablet Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Apixaban by Form - Percentage Breakdown of Value Sales for Capsule Form and Tablet Form for the Years 2014, 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Apixaban by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Apixaban by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Apixaban by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Apixaban Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Apixaban by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Apixaban by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Apixaban by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Apixaban by Form - Capsule Form and Tablet Form - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Apixaban by Form - Capsule Form and Tablet Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Apixaban by Form - Percentage Breakdown of Value Sales for Capsule Form and Tablet Form for the Years 2014, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Apixaban by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Apixaban by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Apixaban by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Apixaban Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Apixaban by Form - Capsule Form and Tablet Form - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Apixaban by Form - Capsule Form and Tablet Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for Apixaban by Form - Percentage Breakdown of Value Sales for Capsule Form and Tablet Form for the Years 2014, 2025 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Apixaban by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Apixaban by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Apixaban by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • INDIA
    • Apixaban Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Apixaban by Form - Capsule Form and Tablet Form - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Apixaban by Form - Capsule Form and Tablet Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: India 16-Year Perspective for Apixaban by Form - Percentage Breakdown of Value Sales for Capsule Form and Tablet Form for the Years 2014, 2025 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Apixaban by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Apixaban by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: India 16-Year Perspective for Apixaban by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Apixaban by Form - Capsule Form and Tablet Form - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Apixaban by Form - Capsule Form and Tablet Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for Apixaban by Form - Percentage Breakdown of Value Sales for Capsule Form and Tablet Form for the Years 2014, 2025 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Apixaban by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Apixaban by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Apixaban by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Apixaban by Form - Capsule Form and Tablet Form - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Apixaban by Form - Capsule Form and Tablet Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Apixaban by Form - Percentage Breakdown of Value Sales for Capsule Form and Tablet Form for the Years 2014, 2025 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Apixaban by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Apixaban by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Apixaban by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Apixaban Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Apixaban by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Apixaban by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for Apixaban by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Apixaban by Form - Capsule Form and Tablet Form - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Apixaban by Form - Capsule Form and Tablet Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Apixaban by Form - Percentage Breakdown of Value Sales for Capsule Form and Tablet Form for the Years 2014, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Apixaban by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Apixaban by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Apixaban by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Apixaban by Form - Capsule Form and Tablet Form - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Apixaban by Form - Capsule Form and Tablet Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for Apixaban by Form - Percentage Breakdown of Value Sales for Capsule Form and Tablet Form for the Years 2014, 2025 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Apixaban by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Apixaban by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Apixaban by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Apixaban by Form - Capsule Form and Tablet Form - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Apixaban by Form - Capsule Form and Tablet Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for Apixaban by Form - Percentage Breakdown of Value Sales for Capsule Form and Tablet Form for the Years 2014, 2025 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Apixaban by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Apixaban by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Apixaban by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Apixaban by Form - Capsule Form and Tablet Form - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Apixaban by Form - Capsule Form and Tablet Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for Apixaban by Form - Percentage Breakdown of Value Sales for Capsule Form and Tablet Form for the Years 2014, 2025 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Apixaban by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Apixaban by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Apixaban by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Apixaban by Form - Capsule Form and Tablet Form - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Apixaban by Form - Capsule Form and Tablet Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for Apixaban by Form - Percentage Breakdown of Value Sales for Capsule Form and Tablet Form for the Years 2014, 2025 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Apixaban by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Apixaban by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Apixaban by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Apixaban Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Apixaban by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Apixaban by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for Apixaban by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Apixaban by Form - Capsule Form and Tablet Form - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Apixaban by Form - Capsule Form and Tablet Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Apixaban by Form - Percentage Breakdown of Value Sales for Capsule Form and Tablet Form for the Years 2014, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Apixaban by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Apixaban by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Apixaban by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Apixaban by Form - Capsule Form and Tablet Form - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Apixaban by Form - Capsule Form and Tablet Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for Apixaban by Form - Percentage Breakdown of Value Sales for Capsule Form and Tablet Form for the Years 2014, 2025 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Apixaban by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Apixaban by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Apixaban by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Apixaban by Form - Capsule Form and Tablet Form - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Apixaban by Form - Capsule Form and Tablet Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for Apixaban by Form - Percentage Breakdown of Value Sales for Capsule Form and Tablet Form for the Years 2014, 2025 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Apixaban by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Apixaban by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Apixaban by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Apixaban by Form - Capsule Form and Tablet Form - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Apixaban by Form - Capsule Form and Tablet Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for Apixaban by Form - Percentage Breakdown of Value Sales for Capsule Form and Tablet Form for the Years 2014, 2025 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Apixaban by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Apixaban by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Apixaban by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Apixaban by Form - Capsule Form and Tablet Form - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Apixaban by Form - Capsule Form and Tablet Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for Apixaban by Form - Percentage Breakdown of Value Sales for Capsule Form and Tablet Form for the Years 2014, 2025 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Apixaban by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Apixaban by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Apixaban by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Apixaban by Form - Capsule Form and Tablet Form - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Apixaban by Form - Capsule Form and Tablet Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for Apixaban by Form - Percentage Breakdown of Value Sales for Capsule Form and Tablet Form for the Years 2014, 2025 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Apixaban by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Apixaban by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Apixaban by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • AFRICA
    • Apixaban Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Apixaban by Form - Capsule Form and Tablet Form - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Apixaban by Form - Capsule Form and Tablet Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for Apixaban by Form - Percentage Breakdown of Value Sales for Capsule Form and Tablet Form for the Years 2014, 2025 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Apixaban by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Apixaban by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Apixaban by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030

IV. COMPETITION